Contact
    Start Publications Tuning the bioactivity of bone morphogenetic protein-2 with ...
    ←  Publication Finder
    QSense

    Tuning the bioactivity of bone morphogenetic protein-2 with surface immobilization strategies

    Year: 2018

    Journal: Acta Biomater., Volume 80, OCT 15, page 108–120

    Authors: Chen, Rui; Yu, Yuanman; Zhang, Wenjing; Pan, Yuanzhong; Wang, Jing; Xiao, Yin; Liu, Changsheng

    Keywords: BMP-2; Osteogenic activity; Immobilization; Heparin; Bone regeneration

    Bone morphogenetic protein-2 (BMP-2) involved therapy is of great potential for bone regeneration. However, its clinical application is restricted due to the undesirable bioactivity and relevant complications in vivo. Immobilization of recombinant BMP-2 (rhBMP-2) is an efficient strategy to mimic natural microenvironment and retain its bioactivity. Herein, we present evidences indicating that osteoinductive capacity of rhBMP-2 can be regulated via variant immobilizing approaches. Three representative superficial immobilizing models were employed to fabricate rhBMP-2-immobilized surfaces including physical adsorption (Au/rhBMP-2), covalent grafting (rhBMP-2-SAM-Au) and heparin binding (Hep-SAM-Au/rhBMP-2) (SAM: self-assembled monolayer). Loading capacity, releasing behavior, osteogenic differentiation and signaling pathways involved, as well as the cellular recognition of rhBMP-2 under various immobilization modes were systematically investigated. As a result, disparate immobilizing approaches not only have effects on loading capacity, but also lead to disparity of osteoinduction at the same dosage. Notably, heparin could reinforce the recognition between rhBMP-2 and its receptors (BMPRs) whereas weaken its binding to its antagonist Noggin. Owing to this selective binding feature, the favorable osteoinduction and maximum ectopic bone formation can be achieved with the heparin-binding approach. In particular, manipulation of orientation-mediated BMP-2-cell recognition efficiency may be a potential target to design more therapeutic efficient rhBMP-2 delivery system. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
    View publication